Literature DB >> 3489763

Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide.

Z K Ballas.   

Abstract

The effect of a sublethal dose of cyclophosphamide (CTX) administered in vivo on murine natural killer (NK) cells, lymphokine-activated killer (LAK) cells, and cytotoxic T lymphocytes (CTL) was examined. It was found that such a dose of CTX abolished all of the killer cell responses examined. The recovery of each response was then examined as a function of time. Allogeneic CTL responses were the first to recover and could be generated from spleen cells obtained 6 days after CTX administration. Fresh NK cell activity recovered by days 9 to 12. However, when spleen cells obtained 12 days after CTX administration were cultured with interleukin 2 (IL 2) for 5 days, they lost the ability to lyse YAC-1 cells, suggesting a distinction between "augmented" and "fresh" NK cell activity. H-2-restricted, trinitrophenyl-specific CTL activity could be generated by day 14 after CTX, provided the cultures were supplemented with exogenous IL 2. LAK could not be induced until day 21 post-CTX treatment. These data suggest that LAK precursors, CTL precursors, and NK cells are distinct cell populations. Additionally, this report introduces a model that may be useful in examining the differential contribution of NK and LAK to successful adoptive tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489763

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.

Authors:  L S Stewart; H F Sewell; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  In vivo treatment with an appropriate anti-Thy-1.2 monoclonal antibody abrogates hybrid resistance to Thy-1.1+ virus-immune effector T cells.

Authors:  P C Doherty; J E Allan; W Allan
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

3.  Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.

Authors:  G R Klimpel; D H Herndon; M D Stein
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

4.  Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Authors:  G R Hill; T Teshima; A Gerbitz; L Pan; K R Cooke; Y S Brinson; J M Crawford; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

5.  A dynamic flux in natural killer cell subsets as a function of the duration of alcohol ingestion.

Authors:  Zuhair K Ballas; Robert T Cook; Michael R Shey; Ruth A Coleman
Journal:  Alcohol Clin Exp Res       Date:  2011-12-07       Impact factor: 3.455

6.  Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.

Authors:  Z Gazit; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

7.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis.

Authors:  E Katsanis; M A Bausero; A C Ochoa; C M Loeffler; B R Blazar; A S Leonard; P M Anderson
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis.

Authors:  Brad E Morrison; Stacy J Park; Jill M Mooney; Borna Mehrad
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

10.  Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2.

Authors:  R Kim; R Lafreniere; K Borkenhagen; L D Bryant
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.